Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous …
HM Kantarjian, M Talpaz, J Cortes, S O'Brien… - Clinical cancer …, 2003 - AACR
Purpose: The purpose of our investigation was to evaluate the response and minimal
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
[引用][C] Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous …
K HM - Clin Cancer Res, 2003 - cir.nii.ac.jp
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib
mesylate (STI571 ; Gleevec) in chronic-phase chronic myelogenous leukemia | CiNii Research …
mesylate (STI571 ; Gleevec) in chronic-phase chronic myelogenous leukemia | CiNii Research …
[引用][C] Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous …
HM KANTARJIAN, M TALPAZ, J CORTES… - Clinical cancer …, 2003 - pascal-francis.inist.fr
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib
mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia CNRS Inist …
mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia CNRS Inist …
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous …
HM Kantarjian, M Talpaz, J Cortes… - … : an official journal …, 2003 - pubmed.ncbi.nlm.nih.gov
Purpose The purpose of our investigation was to evaluate the response and minimal
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous …
HM Kantarjian, M Talpaz, J Cortes… - Clinical Cancer …, 2003 - augusta.elsevierpure.com
Purpose: The purpose of our investigation was to evaluate the response and minimal
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous …
HM Kantarjian, M Talpaz, J Cortes… - Clinical Cancer …, 2003 - mdanderson.elsevierpure.com
Purpose: The purpose of our investigation was to evaluate the response and minimal
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
[PDF][PDF] Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic …
HM Kantarjian, M Talpaz, J Cortes, S O'Brien, S Faderl… - academia.edu
Purpose: The purpose of our investigation was to eval-uate the response and minimal
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous …
HM Kantarjian, M Talpaz, J Cortes… - Clinical Cancer …, 2003 - scholars.northwestern.edu
Purpose: The purpose of our investigation was to evaluate the response and minimal
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous …
HM Kantarjian, M Talpaz, J Cortes… - … Cancer Research: an …, 2003 - europepmc.org
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib
mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. - Abstract - Europe …
mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. - Abstract - Europe …
[引用][C] Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous …
K HM - Clin Cancer Res., 2003 - cir.nii.ac.jp
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib
mesylate (STI571 ; gleevec) in chronic-phase chronic myelogenous leukemia | CiNii Research …
mesylate (STI571 ; gleevec) in chronic-phase chronic myelogenous leukemia | CiNii Research …